Takeda Heterocyclic Compound Patent EP3919055A1
ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Summary
The European Patent Office published Takeda Pharmaceutical Company Limited's patent application EP3919055A1 for heterocyclic compounds. The patent covers novel chemical compositions with potential therapeutic applications in neurological and neurodegenerative disease treatment. Publication Kind A1 indicates the application includes search report.
What changed
Takeda Pharmaceutical Company Limited received publication of EP3919055A1 for heterocyclic compounds classified under C07D 413/04, 413/10, 413/14, and 417/14. The patent application includes pharmaceutical compositions containing these compounds for treating conditions indicated by A61P 25/02 (nervous system disorders) and A61P 25/28 (dementia). Multiple IPC classifications span various oxadiazole, pyridine, and fused heterocycle derivatives.
Pharmaceutical companies and drug manufacturers should note this patent publication for freedom-to-operate assessments and competitive intelligence purposes. No immediate compliance actions are required. The designated states cover major European markets (DE, FR, GB, IT, ES, NL, BE, SE, AT, PL, CH, DK, FI, IE, NO, PT, CZ, HU, RO, SK, SI, EE, LT, LV, BG, HR, MT, CY, LU, IS, LI, MC, MK, SM, RS, TR). Patent validation deadlines in individual EPC contracting states will apply if Takeda pursues national phase protection.
Source document (simplified)
HETEROCYCLIC COMPOUND
Publication EP3919055A1 Kind: A1 Mar 25, 2026
Applicants
Takeda Pharmaceutical Company Limited
Inventors
ITO, Masahiro, YAMAMOTO, Takeshi, KAKEGAWA, Keiko, SUGIYAMA, Hideyuki, MIYAZAKI, Tohru, ARIKAWA, Yasuyoshi, OKAWA, Tomohiro, YONEMORI, Jinichi, KUBO, Osamu, TOITA, Akinori, KOJIMA, Takuto, KIKUCHI, Fumiaki, SASAKI, Minoru, HOMMA, Misaki, IMAEDA, Yasuhiro, MAEZAKI, Hironobu, SASAKI, Shinobu, SATO, Ayumu, KAMITANI, Hirotaka, ASANO, Yasutomi, KOKUBO, Hironori, YOSHIKAWA, Masato
IPC Classifications
C07D 413/04 20060101AFI20221006BHEP C07D 413/10 20060101ALI20221006BHEP C07D 413/14 20060101ALI20221006BHEP C07D 417/14 20060101ALI20221006BHEP C07D 471/04 20060101ALI20221006BHEP A61K 31/4245 20060101ALI20221006BHEP A61K 31/4375 20060101ALI20221006BHEP A61K 31/4439 20060101ALI20221006BHEP A61K 31/444 20060101ALI20221006BHEP A61K 31/4545 20060101ALI20221006BHEP A61K 31/4725 20060101ALI20221006BHEP A61K 31/497 20060101ALI20221006BHEP A61K 31/501 20060101ALI20221006BHEP A61K 31/5025 20060101ALI20221006BHEP A61K 31/504 20060101ALI20221006BHEP A61K 31/506 20060101ALI20221006BHEP A61K 31/536 20060101ALI20221006BHEP A61K 31/5377 20060101ALI20221006BHEP A61P 25/02 20060101ALI20221006BHEP A61P 25/28 20060101ALI20221006BHEP A61P 43/00 20060101ALI20221006BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.